× Current Issue Archive Submit Article
Conflicts of Interest Copyright and Access Open access policy Editorial Policies Peer Review Policy Privacy Statement Publishing Ethics
Editor in chief Associate Editors Advisory Board International Editors
Contact Us About Us Aim & Scope Abstracting And Indexing Author Guidelines Join As Editor
Views: 870 Downloads: 96

PIK3CA mutations and PTEN loss: Effects on neoadjuvant trastuzumab in Vietnamese breast cancer patients


, , , , , , , ,
  1. Department of Pathology, Ho Chi Minh City Oncology Hospital, Ho Chi Minh City, Vietnam.
  2. Center for Molecular Biomedicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.
  3. Cancer Center, Cho Ray Hospital, Ho Chi Minh City, Vietnam.
  4. Department of Pathology, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.
  5. Department of Medical Oncology of Breast Gastroenterology Hepatobiliary Urology, Ho Chi Minh City Oncology Hospital, Ho Chi Minh City, Vietnam.
  6. Department of Breast Surgery, Tam Anh Hospital, Ho Chi Minh City, Vietnam.

Abstract

The objective of this study was to ascertain the prevalence of PIK3CA mutations and PTEN loss in HER2-positive stage II–III Vietnamese breast cancer patients and evaluate their impact on the disease. This case-control study, conducted from January 2019 to June 2022, included 92 patients initially diagnosed with stage II or III breast cancer, confirmed HER2-positive, and treated with neoadjuvant trastuzumab. Post-mastectomy, patients were grouped into pathological complete response (pCR) and pathological partial response (pPR). Each patient was tested for PIK3CA mutations and PTEN loss to examine their correlation with neoadjuvant chemotherapy response. Ninety-two patients completed neoadjuvant chemotherapy and surgery. Among them, 44 (47.8%) achieved complete tumor response, 9 (9.8%) had ductal carcinoma in situ, and 39 (42.4%) had invasive breast cancer. The prevalence of PIK3CA mutations was 16.3%, primarily c.3140A>G (p.H1047R) at exon 20. The rate of PTEN loss was 26.1%. There was no observed correlation between PIK3CA mutation or PTEN loss and neoadjuvant chemotherapy response, with odd ratios of 1.22 (95% CI: 0.93–1.61) and 0.80 (95% CI: 0.63–1.01), respectively. The study revealed no evident correlation between PIK3CA mutations or PTEN loss and the pathological complete response to neoadjuvant chemotherapy. As a result, our findings recommend prudence in the consideration of PIK3CA mutations and PTEN loss as prognostic markers for neoadjuvant chemotherapy response in patients with HER2-positive stage II–III breast cancer.



Keywords: PIK3CA, PTEN, HER2, Breast cancer, Neoadjuvant chemotherapy


How to cite this article:
Vancouver
Kim LB, Vu HA, Anh LT, Ha HTN, Dieu AN, Diem TDK, et al. PIK3CA mutations and PTEN loss: Effects on neoadjuvant trastuzumab in Vietnamese breast cancer patients. J Adv Pharm Educ Res. 2024;14(3):84-9. https://doi.org/10.51847/OEX6hMBb0J
APA
Kim, L. B., Vu, H. A., Anh, L. T., Ha, H. T. N., Dieu, A. N., Diem, T. D. K., Duc, P. T. H., Giang, N. D. T., & Thao, D. T. P. (2024). PIK3CA mutations and PTEN loss: Effects on neoadjuvant trastuzumab in Vietnamese breast cancer patients. Journal of Advanced Pharmacy Education and Research, 14(3), 84-89. https://doi.org/10.51847/OEX6hMBb0J
Citation Formats:

Related articles:
Most viewed articles:


Contact Meral


Meral Publications
www.meralpublisher.com

Davutpasa / Zeytinburnu 34087
Istanbul
Turkey

Email: [email protected]
Tell: +905344998991